Verantos Receives FDA Support to Demonstrate Advanced Approaches to RWE


Verantos announced that it has received a grant award from the U.S. Food and Drug Administration to implement a multi-year advanced real-world evidence (RWE) study.

The program, "Transforming Real-World Evidence with Unstructured and Structured Data to Advance Tailored Therapy" (TRUST), was sponsored by the FDA Center for Drug Evaluation and Research.

As RWE is increasingly used to make clinical assertions and refine the standard of care, rigorous approaches are required to meet evidentiary standards. This three-year study will apply advanced RWE to a clinical scenario, and data quality will be studied by comparing traditional approaches to advanced approaches. The study, FD-20-030, includes innovations in deep phenotyping, data linkage, and phenotype accuracy measurement.

For more information, click here.

Related Videos
Greg Ball, Founder, ASAP Process Consulting image credit screen shot from video
Janice Chang, CEO, TransCelerate BioPharma @ video screenshot.
Applied Clinical Trials and LabConnect
Related Content
© 2024 MJH Life Sciences

All rights reserved.